Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 17:14:1255501.
doi: 10.3389/fphar.2023.1255501. eCollection 2023.

Carnitine metabolites and cognitive improvement in patients with schizophrenia treated with olanzapine: a prospective longitudinal study

Lei Zhao  1 , Hua Liu  1 , Wenjuan Wang  1 , Youping Wang  2   3   4 , Meihong Xiu  5 , Shuyun Li  2   3   4
Affiliations

Carnitine metabolites and cognitive improvement in patients with schizophrenia treated with olanzapine: a prospective longitudinal study

Lei Zhao et al. Front Pharmacol. .

Abstract

Objective: Cognitive impairment is one of the core symptoms of schizophrenia, which is stable and lifelong. L-carnitine has been shown to improve cognitive function and decrease the rate of cognitive deterioration in patients with Alzheimer's disease. However, it remains unclear regarding the role of L-carnitine and its metabolites in cognitive functions in schizophrenia after treatment with olanzapine. The purpose of this study was to evaluate the relationship between changes in plasma levels of L-carnitine metabolites and cognitive improvement after olanzapine treatment. Methods: This was a prospective longitudinal study. In this study, we recruited 25 female patients with first episode schizophrenia (FES) who were drug naïve at baseline and received 4 weeks of olanzapine monotherapy. Cognitive function was assessed at baseline and 4-week follow-up using the RBANS. Plasma L-carnitine metabolite levels were determined by a metabolomics technology based on untargeted ultra-performance liquid chromatography-mass spectrometry (UPLC-MS). Results: We found that the immediate memory index, delayed memory index and RBANS composite score were significantly increased at the 4-week follow-up after treatment. A total of 7 differential L-carnitine metabolites were identified in FES patients after olanzapine monotherapy. In addition, we found that changes in butyrylcarnitine were positively correlated with improvements in language index and RBANS composite score. Further regression analyses confirmed the association between reduced butyrylcarnitine levels and cognitive improvement after olanzapine monotherapy in FES patients. Conclusion: Our study shows that cognitive improvement after olanzapine treatment was associated with changes in L-carnitine metabolite levels in patients with FES, suggesting a key role of L-carnitine in cognition in schizophrenia.

Keywords: carnitines; cognitive improvement; longitudinal study; olanzapine; schizophrenia.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Albaugh V. L., Vary T. C., Ilkayeva O., Wenner B. R., Maresca K. P., Joyal J. L., et al. (2012). Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents. Schizophr. Bull. 38 (1), 153–166. 10.1093/schbul/sbq053 - DOI - PMC - PubMed
    1. Albert N., Randers L., Allott K., Jensen H. D., Melau M., Hjorthøj C., et al. (2019). Cognitive functioning following discontinuation of antipsychotic medication. A naturalistic sub-group analysis from the OPUS II trial. A Nat. sub-group analysis OPUS II trial 49 (7), 1138–1147. 10.1017/S0033291718001836 - DOI - PubMed
    1. Baldez D. P., Biazus T. B., Rabelo-da-Ponte F. D., Nogaro G. P., Martins D. S., Kunz M., et al. (2021). The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: network meta-analyses of randomized controlled trials. Neurosci. Biobehav Rev. 126, 265–275. 10.1016/j.neubiorev.2021.03.028 - DOI - PubMed
    1. Barnett R. (2018). Schizophrenia. Lancet 391 (10121), 648. 10.1016/S0140-6736(18)30237-X - DOI - PubMed
    1. Bilder R. M., Goldman R. S., Robinson D., Reiter G., Bell L., Bates J. A., et al. (2000). Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry 157 (4), 549–559. 10.1176/appi.ajp.157.4.549 - DOI - PubMed